JCC:在溃疡性结肠炎中即使发生部分组织学正常化也不能改善临床结果

2020-10-09 MedSci原创 MedSci原创

溃疡性结肠炎[UC]的特征在于从直肠开始出现的慢性粘膜炎症,并在邻近的结肠持续发炎。

        溃疡性结肠炎[UC]的特征在于从直肠开始出现的慢性粘膜炎症,并在邻近的结肠持续发炎。约有三分之一的患者患有溃疡性直肠炎,三分之一的患者患有左侧UC,另外三分之一的患者患有广泛性结肠炎。对结肠炎范围有限的患者的一线治疗通常是通过直肠滴注局部给药,而疾病范围较大的患者则需要口服治疗。但是对于活动性广泛性结肠炎患者更可能需要进行结肠切除术,并且长期患病的患者其结肠直肠癌的风险更大。UC疾病进展中部分患者会出现部分肠粘膜正常化。有研究显示溃疡性结肠炎患者的完整的组织学正常化和炎症严重程度的降低与临床结局的改善有关,因此,本项研究旨在探究溃疡性结肠炎患者中与节段性组织学正常化相关的患病率,预测因素和临床结果。

 

        研究人员收集了确诊为溃疡性结肠炎并进行了不止一次结肠镜检查的患者的病历。节段性组织学正常化被定义为先前有慢性组织学损伤证据的肠段的组织学正常化。研究人员评估了影响这些发现的变量以及节段正常化是否与改善的临床结局相关。

 

        结果显示:在646例患者中,与其最大疾病程度相比,有32%的患者具有分段和10%的完全组织学正常化。大部分[88%]在近端至远端方向上出现了阶段粘膜正常化。其他人从远端到近端或斑块正常化。在多变量分析中,仅当前吸烟[ p = 0.040]和诊断年龄≤16岁[ p = 0.028]可以预测节段性组织学正常化。在初次结肠镜检查中临床缓解的310位患者中,有77位[25%]在中位1.3年[0.06-7.52]年后经历了临床复发。只有肠道完全组织学正常化才能改善无复发生存率(危险比[HR] 0.23; 95%置信区间[CI] 0.08-0.68;p = 0.008]。

 

        因此,研究人员最后说道UC患者中节段性组织学正常化发生在32%的溃疡性结肠炎患者中,在吸烟或被诊断为较年轻的患者中升高。与完全组织学正常化不同,节段性正常化并不预示着临床结果的改善。

 

 

原始出处:

Britt Christensen. Et al. Segmental Histological Normalisation Occurs in Ulcerative Colitis but Does Not Improve Clinical Outcomes. Journal of Crohn's and Colitis.2020.

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1898854, encodeId=e2061898854bc, content=<a href='/topic/show?id=729322969b9' target=_blank style='color:#2F92EE;'>#临床结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22969, encryptionId=729322969b9, topicName=临床结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Tue Aug 31 09:20:40 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1926281, encodeId=fb841926281e8, content=<a href='/topic/show?id=9238e767680' target=_blank style='color:#2F92EE;'>#组织学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77676, encryptionId=9238e767680, topicName=组织学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Tue Apr 13 05:20:40 CST 2021, time=2021-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1695197, encodeId=5ee6169519eef, content=<a href='/topic/show?id=c76e6645438' target=_blank style='color:#2F92EE;'>#溃疡性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66454, encryptionId=c76e6645438, topicName=溃疡性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=787129789891, createdName=nymo, createdTime=Tue Aug 24 07:20:40 CST 2021, time=2021-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898812, encodeId=4bd38988125e, content=写的很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab81445722, createdName=bosen.huang, createdTime=Thu Nov 12 21:21:19 CST 2020, time=2020-11-12, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1898854, encodeId=e2061898854bc, content=<a href='/topic/show?id=729322969b9' target=_blank style='color:#2F92EE;'>#临床结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22969, encryptionId=729322969b9, topicName=临床结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Tue Aug 31 09:20:40 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1926281, encodeId=fb841926281e8, content=<a href='/topic/show?id=9238e767680' target=_blank style='color:#2F92EE;'>#组织学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77676, encryptionId=9238e767680, topicName=组织学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Tue Apr 13 05:20:40 CST 2021, time=2021-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1695197, encodeId=5ee6169519eef, content=<a href='/topic/show?id=c76e6645438' target=_blank style='color:#2F92EE;'>#溃疡性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66454, encryptionId=c76e6645438, topicName=溃疡性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=787129789891, createdName=nymo, createdTime=Tue Aug 24 07:20:40 CST 2021, time=2021-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898812, encodeId=4bd38988125e, content=写的很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab81445722, createdName=bosen.huang, createdTime=Thu Nov 12 21:21:19 CST 2020, time=2020-11-12, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1898854, encodeId=e2061898854bc, content=<a href='/topic/show?id=729322969b9' target=_blank style='color:#2F92EE;'>#临床结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22969, encryptionId=729322969b9, topicName=临床结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Tue Aug 31 09:20:40 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1926281, encodeId=fb841926281e8, content=<a href='/topic/show?id=9238e767680' target=_blank style='color:#2F92EE;'>#组织学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77676, encryptionId=9238e767680, topicName=组织学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Tue Apr 13 05:20:40 CST 2021, time=2021-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1695197, encodeId=5ee6169519eef, content=<a href='/topic/show?id=c76e6645438' target=_blank style='color:#2F92EE;'>#溃疡性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66454, encryptionId=c76e6645438, topicName=溃疡性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=787129789891, createdName=nymo, createdTime=Tue Aug 24 07:20:40 CST 2021, time=2021-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898812, encodeId=4bd38988125e, content=写的很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab81445722, createdName=bosen.huang, createdTime=Thu Nov 12 21:21:19 CST 2020, time=2020-11-12, status=1, ipAttribution=)]
    2021-08-24 nymo
  4. [GetPortalCommentsPageByObjectIdResponse(id=1898854, encodeId=e2061898854bc, content=<a href='/topic/show?id=729322969b9' target=_blank style='color:#2F92EE;'>#临床结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22969, encryptionId=729322969b9, topicName=临床结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Tue Aug 31 09:20:40 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1926281, encodeId=fb841926281e8, content=<a href='/topic/show?id=9238e767680' target=_blank style='color:#2F92EE;'>#组织学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77676, encryptionId=9238e767680, topicName=组织学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Tue Apr 13 05:20:40 CST 2021, time=2021-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1695197, encodeId=5ee6169519eef, content=<a href='/topic/show?id=c76e6645438' target=_blank style='color:#2F92EE;'>#溃疡性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66454, encryptionId=c76e6645438, topicName=溃疡性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=787129789891, createdName=nymo, createdTime=Tue Aug 24 07:20:40 CST 2021, time=2021-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898812, encodeId=4bd38988125e, content=写的很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab81445722, createdName=bosen.huang, createdTime=Thu Nov 12 21:21:19 CST 2020, time=2020-11-12, status=1, ipAttribution=)]
    2020-11-12 bosen.huang

    写的很好

    0

相关资讯

罗氏2款新药在中国获批临床:CD3/CD20双抗、C5单抗

9月9日,罗氏2款新药在中国获批临床,分别为CD3/CD20双抗RO7082859(弥漫性大B细胞淋巴瘤)和C5单抗RO7112689(阵发性睡眠性血红蛋白尿患者)。

先声药业「艾拉莫德片」治疗原发性干燥综合征临床申请获批

9月8日,先声药业研发的抗风湿新药艾拉莫德片(商品名:艾得辛?)用于治疗原发性干燥综合征(pSS)的新药临床试验申请(受理号CXHL2000340/1/2)获得批准。艾拉莫德片于2011年在全球率先上

面向全球引进人才!清华大学临床医学院发出招贤帖

清华大学临床医学院9日启动全球人才招聘计划,期待能引进海内外高层次医学及相关学科人才。

因志愿者出现疑似严重不良反应,阿斯利康暂停新冠疫苗三期临床试验

当地时间8日,阿斯利康宣布,该公司将暂停一项正在进行的新冠病毒疫苗试验研究,原因是一名志愿者出现疑似严重的不良反应,这也是首个宣布暂停的已进入三期临床试验的新冠候选疫苗。

沉默IL-6表达!优卡迪创新型CAR-T产品获批临床

日前,位于张江科学城的细胞治疗企业上海优卡迪生物医药科技有限公司(以下简称“优卡迪”)的在研产品——具有沉默白介素6表达功能的靶向CD19基因工程化自体

JNNP:自身免疫性疾病的癫痫发作起源:多中心回顾性研究

在过去的几十年中,自身抗体因素已成为原本无法解释的癫痫病的根本原因,并提示了自身免疫 和癫痫病之间的联系。除了由炎症引起的癫痫发作易感性增加外,许多特定的自身抗体还具有直接的致癫痫作用。在这些基础上,